Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

ClinicalTrials.gov ID: NCT07621718

Public ClinicalTrials.gov record NCT07621718. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

RASolute 305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (Modified FOLFIRINOX or Gemcitabine Plus Nab-Paclitaxel) With or Without Zoldonrasib (RMC-9805) as First-line Treatment in Patients With Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with chemotherapy compared to placebo in combination with chemotherapy.

Study identification

NCT ID: NCT07621718
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Revolution Medicines, Inc.; Industry
Enrollment: 670 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 22, 2026 (Actual)
Primary completion: Dec 30, 2028 (Estimated)
Completion: Apr 22, 2030 (Estimated)
Last update posted: Oct 13, 2026

2026 – 2030

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 17

Facility	City	State	ZIP	Site status
Mayo Clinic Arizona	Phoenix	Arizona	85054	Recruiting
The University of Arizona Cancer Center-North Campus	Tucson	Arizona	85719	Recruiting
Yale University	New Haven	Connecticut	06511	Recruiting
University of Florida	Gainesville	Florida	32610	Recruiting
Mayo Clinic Florida	Jacksonville	Florida	32224	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Piedmont Cancer Institute	Atlanta	Georgia	30318	Recruiting
Piedmont Healthcare	Atlanta	Georgia	30318	Recruiting
University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
Johns Hopkins University	Baltimore	Maryland	21287	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Mayo Clinic Rochester	Rochester	Minnesota	55905	Recruiting
Astera Cancer Care	East Brunswick	New Jersey	08816	Recruiting
Rutgers Cancer University	New Brunswick	New Jersey	08901	Recruiting
Columbia University Irving Medical Center	New York	New York	10032	Recruiting
Duke Cancer Center	Durham	North Carolina	27710	Recruiting
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	37232	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07621718, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 13, 2026 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07621718 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →